Why Transplant Surgeons Get Sued: The Mismatch, the Thrombosis, and the Rejection

By John Mahoney · June 2026 · 8 min read

Transplant surgery is a low-volume specialty with some of the highest stakes in medicine, and that combination makes it one of the hardest fields to litigate cleanly. The claims that come are rarely about a single surgeon's hand slipping. They are about a system — the matching lab, the procurement team, the surgeon, the transplant nephrologist or hepatologist, the immunosuppression service, and the recall and follow-up apparatus — that allowed an irreversible harm to reach the patient. An attorney who frames a transplant case as a simple operative-error file will miss where the negligence actually lives, and will pick the wrong expert to prove it. This guide explains where transplant liability concentrates, the cannot-miss failures behind it, and what separates a strong case from a weak one — for plaintiff and defense med-mal attorneys.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Transplant outcomes are governed by recognized baseline complication rates, and many adverse events occur without any negligence; treat the patterns below as directional, verify against the controlling jurisdiction and the applicable standard of care, and value any individual case on its own record.

The Frequency-and-Severity Reality

By frequency, transplant surgery generates relatively few malpractice claims compared with high-volume specialties, simply because the procedure volume is small and the patient pool is highly selected and intensely monitored. Most of these patients are managed by multidisciplinary teams at academic centers with structured protocols, which suppresses the kind of isolated, idiosyncratic error that fuels claims elsewhere. The cumulative exposure for any individual transplant surgeon is real, but the annual claim count for the field is low relative to its visibility.

Severity, by contrast, sits at the top of the scale. When a transplant claim does mature, the alleged harm is commonly catastrophic and irreversible — graft loss, the need for re-transplantation, life-threatening infection, organ-transmitted disease or malignancy, or death — in a patient who started from a precarious baseline. Damages models routinely involve a lost organ that cannot be replaced without another scarce donor, a return to dialysis or a transplant waitlist, and lifelong consequences. The valuation lesson is that transplant is the inverse of a high-frequency specialty: few claims, but each surviving one carries outsized severity and demands a systems-level proof, not a single-defendant theory.

The Dominant Allegation Types

Transplant claims cluster into a matching-and-procurement group, a technical-operative group, and a post-transplant-management group, with informed consent running through all of them:

• Matching and crossmatch error — ABO blood-group incompatibility, donor-recipient mismatch, or a missed or misread crossmatch that leads to hyperacute or antibody-mediated rejection. These are among the most indefensible allegations because they read as preventable systems failures.
• Technical vascular and biliary complications — hepatic, renal, or other arterial thrombosis, portal or venous thrombosis, anastomotic failure, and biliary leak or stricture, with claims framed around operative technique or failure to recognize and rescue the complication in time.
• Primary graft non-function and delayed recognition of rejection — failure to identify a failing or rejecting graft early enough to intervene, often a monitoring-and-follow-up allegation rather than an operative one.
• Immunosuppression-management injury — opportunistic infection, drug toxicity, and post-transplant malignancy attributed to over- or under-immunosuppression or inadequate prophylaxis and surveillance.
• Donor-transmitted disease or malignancy — transmission of infection or cancer from the donor organ, tied to procurement screening and organ-acceptance decisions.
• Organ-allocation and listing disputes — claims over waitlist placement, listing or de-listing decisions, and allocation, which raise distinctive governance and policy questions.
• Lack of informed consent — central to every transplant, given a high-risk operation, a scarce organ, lifelong immunosuppression, and a wide range of disclosed complications.

The structural point: relatively few of these claims turn on a single surgeon's intraoperative technique alone. Most implicate a chain — the lab, the procurement team, the operating surgeon, and the post-transplant service — and the merit analysis has to trace that chain rather than stop at the operating room.

The Cannot-Miss Conditions and Failures

The conditions and failures that drive transplant litigation are:

• ABO incompatibility and crossmatch failure. The highest-exposure allegation. A blood-group or crossmatch error that triggers hyperacute or antibody-mediated rejection reads to a jury as a preventable verification failure, and the chart of who ran, checked, and signed off on the match is decisive.
• Vascular thrombosis — hepatic or renal artery, portal or other venous. A leading cause of early graft loss; the recurring failure is delayed recognition on imaging or labs and a missed window to re-operate or revascularize.
• Biliary leak and stricture — a common complication of liver transplant; claims turn on recognition and timely management, not the mere occurrence.
• Primary graft non-function and delayed rejection — failure to monitor graft function, act on rising markers or biopsy findings, and escalate immunosuppression before the graft is lost.
• Opportunistic infection, drug toxicity, and post-transplant malignancy — the downstream consequences of immunosuppression management, where surveillance, prophylaxis, and dose adjustment define the standard.
• Donor-transmitted infection or cancer — failure in donor screening or organ-acceptance judgment that delivers disease with the graft.

For the matching and procurement side, the single most actionable screening question is the verification question: who confirmed ABO compatibility and the crossmatch, when, and against what source document — and does the record close that loop? For the technical and management side, the decisive question is timing: when did the team have data suggesting thrombosis, non-function, rejection, or infection, and how long did recognition and rescue take?

The Contributing Factors That Drive Payouts

Across transplant closed claims, the recurring contributing factors are:

• Systems and verification failure — the distinctive transplant amplifier. ABO and crossmatch errors, mislabeled specimens, and handoff gaps between the matching lab, procurement, and the operating team turn an individual into a systems claim and weaken the defense substantially.
• Clinical judgment and timing — the costliest factor in the technical and management cases: delayed recognition of vascular thrombosis, biliary complications, graft non-function, or rejection, and a missed window to re-operate or escalate therapy.
• Surveillance and immunosuppression management — inadequate monitoring, prophylaxis, or dose adjustment that allows opportunistic infection, drug toxicity, or post-transplant malignancy to develop and progress.
• Donor evaluation and organ-acceptance judgment — screening and acceptance decisions behind donor-transmitted disease, where the question is what was known or knowable at procurement.
• Communication and informed consent — failure to convey the operative risk, the realistic graft-survival expectations, and the lifelong immunosuppression burden; transplant consent is unusually broad, and gaps in it surface in nearly every claim.
• Documentation and handoffs — incomplete records of the match verification, intraoperative findings, monitoring trends, and result-notification follow-up across a multidisciplinary, multi-shift team.

Two of these are transplant-specific levers. The first is the systems-and-verification amplifier: because so many of these cases run through a lab, a procurement team, and multiple services, the negligence is frequently in a handoff rather than a hand, and identifying which link broke reframes both liability and the roster of defendants. The second is the timing record: in a thrombosis, non-function, or rejection case, the line between a defensible file and a paid claim is usually whether the chart shows the team saw the warning data and how fast they acted — the rescue window, captured in the record, often decides the case.

Strong Case vs. Weak Case in Transplant Surgery Malpractice

The same factors grade the file, and the framing is useful to both sides.

What makes a transplant case strong (plaintiff) / dangerous (defense)

• An ABO-incompatible transplant or a missed or misread crossmatch, with a verification trail that shows the check was skipped, overridden, or never closed — a clean preventable-systems failure.
• Imaging or laboratory data signaling vascular thrombosis, graft non-function, or rejection that sat unaddressed while the rescue window closed, supporting a strong causation theory tied to the delay.
• Donor-transmitted infection or malignancy where screening or acceptance documentation shows the risk was identifiable and not acted on.
• A high-risk operation or immunosuppression course with absent or generic informed consent that did not match the realized, disclosed-or-undisclosed complication.

What makes a transplant case weak (plaintiff) / defensible (defense)

• A fully documented match-verification loop — ABO and crossmatch confirmed against source documents and signed off — with the adverse outcome attributable to a recognized, non-negligent complication rate.
• A complication that was a disclosed, known risk of the procedure, with documented informed consent and realistic graft-survival counseling, framing the harm as an accepted risk rather than negligence.
• A record showing prompt recognition and appropriate rescue — timely imaging, re-operation, or escalation of immunosuppression — consistent with the standard of care.
• A patient whose course was driven by non-adherence to immunosuppression, missed surveillance visits, or comorbidities rather than any team failure.

Transplant rewards a systems-level triage. On the matching and procurement side, the case lives or dies on the verification loop and whether a preventable error reached the patient. On the technical and management side, it turns on timing — the warning data, the rescue window, and how the multidisciplinary team responded. Whichever side you are on, grading the file means tracing the chain across the lab, the procurement team, the surgeon, and the transplant service, and pressure-testing the expert who will carry that causation story.

Bottom Line

Transplant surgeons get sued rarely, but the claims that survive carry some of the highest severity in medicine, and almost none of them are simple. The harm is usually catastrophic and irreversible, and the negligence usually lives in a system — the matching lab, the procurement team, the operating surgeon, and the post-transplant service — rather than in a single set of hands. The cannot-miss facts are the unverified ABO or crossmatch, the thrombosis or graft non-function recognized too late, the rejection that outran the monitoring, the immunosuppression complication that surveillance should have caught, the disease that came with the donor organ, and the broad consent that did not match the harm. Whether you are screening these cases for the plaintiff or defending them, triage first to the right link in the chain — matching, technical, or management — and grade the file on the verification loop, the rescue window, and the documented consent, not on the gravity of the outcome alone.

Questions? Contact us at [email protected] or (856) 979-6525

🔎 Screening a case in a different specialty? Browse all 70 specialty malpractice-risk guides in one place — Why Doctors Get Sued: Malpractice Risk by Specialty →